One-step mixing with humanized anti-mPEG bispecific antibody enhances tumor accumulation and therapeutic efficacy of mPEGylated nanoparticles

Biomaterials

Volumn 35, Issue 37, 2014, Pages 9930-9940

  Kao, Chien Han ^a   Wang, Jaw Yuan ^a   Chuang, Kuo Hsiang ^b   Chuang, Chih Hung ^c   Cheng, Ta Chun ^b   Hsieh, Yuan Chin ^a   Tseng, Yun long ^d   Chen, Bing Mae ^e   Roffler, Steve R ^e   Cheng, Tian Lu ^c,f  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d Taipei   (Taiwan)

^e INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^f NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

Bispecific antibody; Cancer imaging; Methoxy poly(ethylene glycol); PEGylated nanoparticle; Targeted therapy

Indexed keywords

ANTIBODIES; CYTOLOGY; DISEASES; DRUG DELIVERY; MEDICAL IMAGING; MIXING; MOLECULES; NANOPARTICLES; POLYETHYLENE GLYCOLS; TUMORS;

ANTICANCER ACTIVITIES; CANCER IMAGING; LIPOSOMAL DOXORUBICIN; METHOXYPOLYETHYLENE GLYCOL; PEGYLATED NANOPARTICLE; PHYSIOLOGICAL CONDITION; TARGETED THERAPY; THERAPEUTIC EFFICACY;

CELLS;

BISPECIFIC ANTIBODY; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MACROGOL; NANOPARTICLE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; ANTINEOPLASTIC ANTIBIOTIC; DRUG CARRIER; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY; MONOMETHOXYPOLYETHYLENE GLYCOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL KILLING; CELL SURFACE; CONTROLLED STUDY; CYTOTOXICITY; FLUORESCENCE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; 3T3 CELL LINE; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DIAGNOSTIC USE; DRUG DELIVERY SYSTEM; FEMALE; FLUORESCENCE IMAGING; NEOPLASMS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL, HUMANIZED; BALB 3T3 CELLS; CELL LINE, TUMOR; DOXORUBICIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED BALB C; MICE, NUDE; NANOPARTICLES; NEOPLASMS; OPTICAL IMAGING; POLYETHYLENE GLYCOLS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 84907260836     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.08.032     Document Type: Article

References (51)

1. Woodle M.C., Lasic D.D. Sterically stabilized liposomes. Biochim Biophys Acta 1992, 1113:171-199.
2. Alexis F., Pridgen E., Molnar L.K., Farokhzad O.C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008, 5:505-515.
3. He Q., Zhang Z., Gao F., Li Y., Shi J. Invivo biodistribution and urinary excretion of mesoporous silica nanoparticles: effects of particle size and PEGylation. Small 2011, 7:271-280.
4. Yang S.T., Fernando K., Liu J.H., Wang J., Sun H.F., Liu Y., et al. Covalently PEGylated carbon nanotubes with stealth character invivo. Small 2008, 4:940-944.
5. Gabizon A.A. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 2001, 19:424-436.
6. Wang A.Z., Langer R., Farokhzad O.C. Nanoparticle delivery of cancer drugs. Annu Rev Med 2012, 63:185-198.
7. Riggio C., Pagni E., Raffa V., Cuschieri A. Nano-oncology: clinical application for cancer therapy and future perspectives. JNanomater 2011, 2011:17-26.
8. Jokerst J.V., Lobovkina T., Zare R.N., Gambhir S.S. Nanoparticle PEGylation for imaging and therapy. Nanomedicine 2011, 6:715-728.
9. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001, 41:189-207.
10. Modi S., Jain P., Domb A.J., Kumar N. Exploiting EPR in polymer drug conjugate delivery for tumor targeting. Curr Pharm Des 2006, 12:4785-4796.
11. Yuan F., Leunig M., Huang S.K., Berk D.A., Papahadjopoulos D., Jain R.K. Mirovascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 1994, 54:3352-3356.
12. Jang S.H., Wientjes M.G., Lu D., Au J.L.S. Drug delivery and transport to solid tumors. Pharm Res 2003, 20:1337-1350.
13. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2:751-760.
14. Bhattacharyya S., Bhattacharya R., Curley S., McNiven M.A., Mukherjee P. Nanoconjugation modulates the trafficking and mechanism of antibody induced receptor endocytosis. Proc Natl Acad Sci U S A 2010, 107:14541-14546.
15. Kirpotin D.B., Drummond D.C., Shao Y., Shalaby M.R., Hong K., Nielsen U.B., et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 2006, 66:6732-6740.
16. Pirollo K.F., Chang E.H. Does a targeting ligand influence nanoparticle tumor localization or uptake?. Trends Biotechnol 2008, 26:552-558.
17. Popovtzer R., Agrawal A., Kotov N.A., Popovtzer A., Balter J., Carey T.E., et al. Targeted gold nanoparticles enable molecular CT imaging of cancer. Nano Lett 2008, 8:4593-4596.
18. Satpathy M., Wang L., Zielinski R., Qian W., Lipowska M., Capala J., et al. Active targeting using HER-2-affibody-conjugated nanoparticles enabled sensitive and specific imaging of orthotopic HER-2 positive ovarian tumors. Small 2013, 10:544-555.
19. Manjappa A.S., Chaudhari K.R., Venkataraju M.P., Dantuluri P., Nanda B., Sidda C., et al. Antibody derivatization and conjugation strategies: application in preparation of stealth immunoliposome to target chemotherapeutics to tumor. JControl Release 2011, 150:2-22.
20. Bendas G., Krause A., Bakowsky U., Vogel J., Rothe U. Targetability of novel immunoliposomes prepared by a new antibody conjugation technique. Int J Pharm 1999, 181:79-93.
21. Nobs L., Buchegger F., Gurny R., Allemann E. Current methods for attaching targeting ligands to liposomes and nanoparticles. JPharm Sci 2004, 93:1980-1992.
22. Feng B., Tomizawa K., Michiue H., Miyatake S.-i., Han X.-J., Fujimura A., et al. Delivery of sodium borocaptate to glioma cells using immunoliposome conjugated with anti-EGFR antibodies by ZZ-His. Biomaterials 2009, 30:1746-1755.
23. Goldman E.R., Anderson G.P., Tran P.T., Mattoussi H., Charles P.T., Mauro J.M. Conjugation of luminescent quantum dots with antibodies using an engineered adaptor protein to provide new reagents for fluoroimmunoassays. Anal Chem 2002, 74:841-847.
24. Su Y.C., Chen B.M., Chuang K.H., Cheng T.L., Roffler S.R. Sensitive quantification of PEGylated compounds by second-generation anti-poly (ethylene glycol) monoclonal antibodies. Bioconjug Chem 2010, 21:1264-1270.
25. Chuang K.-H., Wang H.-E., Cheng T.-C., Tzou S.-C., Tseng W.-L., Hung W.-C., et al. Development of a universal anti-polyethylene glycol reporter gene for noninvasive imaging of PEGylated probes. JNucl Med 2010, 51:933-941.
26. Makabe K., Nakanishi T., Tsumoto K., Tanaka Y., Kondo H., Umetsu M., et al. Thermodynamic consequences of mutations in vernier zone residues of a humanized anti-human epidermal growth factor receptor murine antibody, 528. JBiol Chem 2008, 283:1156-1166.
27. Rydzanicz R., Zhao X.S., Johnson P.E. Assembly PCR oligo maker: a tool for designing oligodeoxynucleotides for constructing long DNA molecules for RNA production. Nucleic Acids Res 2005, 33:W521-W525.
28. Shahied L.S., Tang Y., Alpaugh R.K., Somer R., Greenspon D., Weiner L.M. Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. JBiol Chem 2004, 279:53907-53914.
29. Chuang K.-H., Cheng C.-M., Roffler S.R., Lu Y.-L., Lin S.-R., Wang J.-Y., et al. Combination cancer therapy by hapten-targeted prodrug-activating enzymes and cytokines. Bioconjug Chem 2006, 17:707-714.
30. Brezinsky S., Chiang G., Szilvasi A., Mohan S., Shapiro R., MacLean A., et al. Asimple method for enriching populations of transfected CHO cells for cells of higher specific productivity. JImmunol Methods 2003, 277:141-155.
31. Kirpotin D., Park J.W., Hong K., Zalipsky S., Li W.-L., Carter P., et al. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells invitro. Biochemistry 1997, 36:66-75.
32. Baselga J., Albanell J. Mechanism of action of anti-HER2 monoclonal antibodies. Ann Oncol 2001, 12:S35-S41.
33. Spano J., Fagard R., Soria J.-C., Rixe O., Khayat D., Milano G. Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives. Ann Oncol 2005, 16:189-194.
34. Gao J., Liu W., Xia Y., Li W., Sun J., Chen H., et al. The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through anti-EGFR antibody conjugation by immunoliposomes. Biomaterials 2011, 32:3459-3470.
35. Cheng T.-L., Cheng C.-M., Chen B.-M., Tsao D.-A., Chuang K.-H., Hsiao S.-W., et al. Monoclonal antibody-based quantitation of poly (ethylene glycol)-derivatized proteins, liposomes, and nanoparticles. Bioconjug Chem 2005, 16:1225-1231.
36. Cheng T.-L., Wu P.-Y., Wu M.-F., Chern J.-W., Roffler S.R. Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM. Bioconjug Chem 1999, 10:520-528.
37. Schnyder A., Krahenbuhl S., Torok M., Drewe J., Huwyler J. Targeting of skeletal muscle invitro using biotinylated immunoliposomes. Biochem J 2004, 377:61.
38. Jin T., Tiwari D.K., Tanaka S.-i., Inouye Y., Yoshizawa K., Watanabe T.M. Antibody-proteinA conjugated quantum dots for multiplexed imaging of surface receptors in living cells. Mol Biosyst 2010, 6:2325-2331.
39. Léonetti M., Thai R., Cotton J., Leroy S., Drevet P., Ducancel F., et al. Increasing immunogenicity of antigens fused to Ig-binding proteins by cell surface targeting. JImmunol 1998, 160:3820-3827.
40. Xiao Z., McQuarrie S., Suresh M., Mercer J., Gupta S., Miller G. Athree-step strategy for targeting drug carriers to human ovarian carcinoma cells invitro. JBiotechnol 2002, 94:171-184.
41. Schneider B., Grote M., John M., Haas A., Bramlage B. Targeted siRNA delivery and mRNA knockdown mediated by bispecific digoxigenin-binding antibodies. Mol Ther Nucleic Acids 2012, 1:e46.
42. Hwang W.Y.K., Foote J. Immunogenicity of engineered antibodies. Methods 2005, 36:3-10.
43. Scott A.M., Wolchok J.D., Old L.J. Antibody therapy of cancer. Nat Rev Cancer 2012, 12:278-287.
44. Rodwell J.D., Alvarez V.L., Lee C., Lopes A.D., Goers J., King H.D., et al. Site-specific covalent modification of monoclonal antibodies: invitro and invivo evaluations. Proc Natl Acad Sci U S A 1986, 83:2632-2636.
45. Lu R.-M., Chang Y.-L., Chen M.-S., Wu H.-C. Single chain anti-c-Met antibody conjugated nanoparticles for invivo tumor-targeted imaging and drug delivery. Biomaterials 2011, 32:3265-3274.
46. Koning G.A., Kamps J.A., Scherphof G.L. Efficient intracellular delivery of 5-fluorodeoxyuridine into colon cancer cells by targeted immunoliposomes. Cancer Detect Prev 2002, 26:299-307.
47. Sapra P., Allen T. Ligand-targeted liposomal anticancer drugs. Prog Lipid Res 2003, 42:439-462.
48. Frieden E. Non-covalent interactions: key to biological flexibility and specificity. JChem Educ 1975, 52:754-761.
49. Dvir T., Bauer M., Schroeder A., Tsui J.H., Anderson D.G., Langer R., et al. Nanoparticles targeting the infarcted heart. Nano Lett 2011, 11:4411-4414.
50. Veeranarayanan S., Poulose A.C., Mohamed M.S., Varghese S.H., Nagaoka Y., Yoshida Y., et al. Synergistic targeting of cancer and associated angiogenesis using triple-targeted dual-drug silica nanoformulations for theragnostics. Small 2012, 8:3476-3489.
51. Chen F., Cai W. Tumor vasculature targeting: a generally applicable approach for functionalized nanomaterials. Small 2014, 10:1887-1893.